Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.

Autor: Westin SN; University of Texas MD Anderson Cancer Center, Houston, TX., Moore K; Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma, OK., Chon HS; H.Lee Moffitt Cancer Center, Tampa, FL., Lee JY; Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea., Thomes Pepin J; Minnesota Oncology, Minneapolis, MN., Sundborg M; FirstHealth Moore Regional Hospital, Pinehurst, NC., Shai A; RAMBAM Health Care Campus, Haifa, and Israeli Society of Gynecologic Oncology (ISGO), Israel., de la Garza J; Texas Oncology-San Antonio Medical Center, San Antonio, TX., Nishio S; Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka, Japan., Gold MA; Oklahoma Cancer Specialists and Research Institute, Tulsa, OK., Wang K; Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., McIntyre K; Texas Health Presbyterian Hospital, Dallas, TX., Tillmanns TD; West Cancer Center Research Institute & University of Tennessee Health Science Center, Memphis, TN., Blank SV; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, and GOG Foundation (GOG-F), USA., Liu JH; Sun Yat-sen University Cancer Center, Guangzhou, China., McCollum M; Virginia Oncology Associates, Brock Cancer Center, Norfolk, VA, and GOG Foundation (GOG-F), USA., Contreras Mejia F; National Cancer Institute of Colombia, Bogotá, Colombia., Nishikawa T; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Pennington K; Fred Hutchinson Cancer Center, University of Washington Medical Center, Seattle, WA., Novak Z; National Institute of Oncology, Budapest, and Central and Eastern European Gynecologic Oncology Group (CEEGOG), Hungary., De Melo AC; Clinical Research and Technological Development Division, Brazilian National Cancer Institute, Rio de Janeiro, Brazil., Sehouli J; Charité-Department of Gynecology with Center of Oncological Surgery, Universitätsmedizin Berlin, Berlin, and North Eastern German Society of Gynecological Oncology (NOGGO), Germany., Klasa-Mazurkiewicz D; Department of Obstetrics and Gynecology, Gynecological Oncology and Gynecological Endocrinology, Medical University of Gdańsk, Gdańsk, and Polish Gynecologic Oncology Group (PGOG), Poland., Papadimitriou C; Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, and Hellenic Cooperative Oncology Group (HeCOG), Greece., Gil-Martin M; Medical Oncology Department, Catalan Institute of Oncology-Institut d'Investigació Biomédica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L'Hospitalet-Barcelona, Barcelona, and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Spain., Brasiuniene B; Department of Medical Oncology, National Cancer Institute of Lithuania, Faculty of Medicine of Vilnius University, Vilnius, and Nordic Society of Gynaecological Oncology (NSGO), Lithuania., Donnelly C; Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom., Del Rosario PM; Oncology R&D, Global Medicines Development, AstraZeneca, Cambridge, United Kingdom., Liu X; Oncology R&D, Late-stage Development, AstraZeneca, Gaithersburg, MD., Van Nieuwenhuysen E; University Hospital Leuven, Leuven, and Luxembourg Gynaecological Oncology Group (BGOG), Belgium.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jan 20; Vol. 42 (3), pp. 283-299. Date of Electronic Publication: 2023 Oct 21.

FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways.

Autor: Huo X; School of Basic Medical Sciences, Capital Medical University, Beijing, China.; Department of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.; Center for Cancer Research, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States., Zhang W; Department of Genetics, Genomics & Informatics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States., Zhao G; Department of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.; Center for Cancer Research, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States., Chen Z; School of Basic Medical Sciences, Capital Medical University, Beijing, China., Dong P; Department of Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan., Watari H; Department of Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan., Narayanan R; Center for Cancer Research, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.; Department of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States., Tillmanns TD; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, West Cancer Center, Germantown, TN, United States., Pfeffer LM; Department of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.; Center for Cancer Research, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States., Yue J; Department of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.; Center for Cancer Research, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Apr 28; Vol. 12, pp. 851065. Date of Electronic Publication: 2022 Apr 28 (Print Publication: 2022).

Use of a web-based app to improve postoperative outcomes for patients receiving gynecological oncology care: A randomized controlled feasibility trial.

Autor: Graetz I; College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN 38163, United States. Electronic address: igraetz@uthsc.edu., Anderson JN; College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN 38163, United States., McKillop CN; Department of Economics, State University of New York at Cortland, 28 Graham Ave., Cortland, NY 13045, United States., Stepanski EJ; College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN 38163, United States; Vector Oncology, 6555 Quince Rd #400, Memphis, TN 38119, United States., Paladino AJ; College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN 38163, United States., Tillmanns TD; College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN 38163, United States; West Cancer Center, 7945 Wolf River Blvd, Germantown, TN 38138, United States.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2018 Aug; Vol. 150 (2), pp. 311-317. Date of Electronic Publication: 2018 Jun 11.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.